Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28146075 | 0.86 | MEN1 (0.60) | ALDH1A1LMNAMAPTMAPK1LCK | |
| SCHEMBL3790475 | 0.85 | PDK1 (0.54) | ALDH1A1LMNAHTTSMN1; SMN2KDM4E | |
| SCHEMBL30207788 | 0.85 | PDK1 (0.54) | ALDH1A1LMNAHTTSMN1; SMN2KDM4E | |
| SCHEMBL2986447 | 0.85 | KDM4E (0.58) | ALDH1A1LMNAPOLBMAPTHTT | |
| SCHEMBL3790491 | 0.84 | LCK (0.52) | ALDH1A1LMNAPOLBP2RX7MAPK1 | |
| SCHEMBL16812449 | 0.84 | ALDH1A1 (0.47) | ALDH1A1LMNAPOLBMAPTP2RX7 | |
| SCHEMBL3784448 | 0.83 | GPR35 (0.50) | ALDH1A1LMNAPOLBP2RX7MAPK1 | |
| SCHEMBL2091197 | 0.83 | ALDH1A1 (0.73) | ALDH1A1LMNAPOLBMAPTHTT | |
| SCHEMBL12517737 | 0.83 | RXFP1 (0.46) | ALDH1A1LMNAPOLBP2RX7MAPK1 | |
| SCHEMBL15296459 | 0.83 | ALDH1A1 (0.46) | ALDH1A1LMNAPOLBP2RX7MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411398-B1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-8785651-B2 | Method for manufacturing a boronic acid ester compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20120123122-A1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | GENENTECH, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2411398-A1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010110782-A1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-30 | — | — | WO | disclosed |
| EP-1660484-B1 | METHYL INDOLES AND METHYL PYRROLOPYRIDINES AS ALPHA-1 ADRENERGIC AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-08-27 | — | — | EP | disclosed |
| EP-1660484-B1 | METHYL INDOLES AND METHYL PYRROLOPYRIDINES AS ALPHA-1 ADRENERGIC AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-08-27 | — | — | EP | disclosed |
| EP-1660484-A1 | METHYL INDOLES AND METHYL PYRROLOPYRIDINES AS ALPHA-1 ADRENERGIC AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-31 | — | — | EP | disclosed |
| US-6979696-B2 | Method for detecting a gram-negative bacterial autoinducer molecule | ROCHE PALO ALTO LLC (US) | 2005-12-27 | — | — | US | disclosed |
| WO-2004099189-A1 | METHYL INDOLES AND METHYL PYRROLOPYRIDINES AS ALPH-1 ADRENERGIC AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-18 | — | — | WO | disclosed |
| US-20040224973-A1 | Substituted indoles as alpha-1 agonists | ROCHE PALO ALTO LLC | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224973-A1 | Substituted indoles as alpha-1 agonists | ADRA1A, ADRB1, ADRA1D | ALDH1A1 408/4885LMNA 1781/4885POLB 3963/4885 |
| US-20120123122-A1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | NISCH, BRSK1, BLK | ALDH1A1 4174/4885LMNA 4073/4885POLB 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.